Who benefits from a tumor bed boost after whole-breast radiotherapy?
Menée à partir de données portant sur 1 616 patientes atteintes d'un cancer du sein traité par chirurgie conservatrice, radiothérapie du sein entier puis éventuellement radiothérapie de type "boost" (durée médiane de suivi : 18,2 ans), cette étude identifie les facteurs associés à une récidive ipsilatérale
In an effort to determine the optimal dose of radiotherapy after breast-conserving surgery, the European Organization for Research and Treatment of Cancer (EORTC) conducted a trial between 1989 and 1996.2 They randomized 5569 patients treated with breast conservation surgery followed by whole breast radiation to 50 Gy to no boost vs an additional 16 Gy directed to the tumor bed. At 20 years of follow-up, the risk of ipsilateral breast tumor recurrence (IBTR) was significantly reduced (hazard ratio, 0.65; P < .001) with the addition of a boost. The largest absolute benefit was seen in younger patients.2
JAMA Oncology , éditorial en libre accès, 2015